Welcome to LookChem.com Sign In|Join Free

CAS

  • or

900175-12-4

Post Buying Request

900175-12-4 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

900175-12-4 Usage

Uses

5-Ethoxy-2,4-difluorophenylboronic acid

Check Digit Verification of cas no

The CAS Registry Mumber 900175-12-4 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 9,0,0,1,7 and 5 respectively; the second part has 2 digits, 1 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 900175-12:
(8*9)+(7*0)+(6*0)+(5*1)+(4*7)+(3*5)+(2*1)+(1*2)=124
124 % 10 = 4
So 900175-12-4 is a valid CAS Registry Number.

900175-12-4SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 12, 2017

Revision Date: Aug 12, 2017

1.Identification

1.1 GHS Product identifier

Product name (5-Ethoxy-2,4-difluorophenyl)boronic acid

1.2 Other means of identification

Product number -
Other names (5-ethoxy-2,4-difluorophenyl)boronic acid

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:900175-12-4 SDS

900175-12-4Upstream product

900175-12-4Relevant articles and documents

PHENYLGLYCINAMIDE DERIVATIVES USEFUL AS ANTICOAGULANTS

-

Page/Page column 169-170, (2008/06/13)

The present invention relates generally to phenylglycinamide derivatives that inhibit serine proteases. In particular it is directed to novel phenylglycinamide derivatives, and analogues thereof, which are useful as selective inhibitors of serine protease enzymes of the coagulation cascade; for example thrombin, factor VIIa, factor Xa, factor XIa, factor IXa, and/or plasma kallikrein. In particular, it relates to compounds that are factor VIIa inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of using the same.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 900175-12-4